News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Depomed, Inc. Completes Enrollment of Phase 3 Clinical Program of DM-1796 in Post-Herpetic Neuralgia
June 2, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that it has completed enrollment of the Phase 3 clinical trial of DM-1796 for the treatment of post-herpetic neuralgia.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
Weight loss
Viking Crashes as Obesity Pill Delivers Over 12% Weight Loss
August 19, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides
August 19, 2025
·
5 min read
·
Nick Paul Taylor
Sickle cell disease
Pfizer’s $5.4B GBT Bet Disappoints Again as Sickle Cell Therapy Fails in Phase III
August 18, 2025
·
2 min read
·
Tristan Manalac
Obesity
Eli Lilly Keeps Obesity Pipeline Fresh With $1.3B Superluminal Partnership
August 14, 2025
·
1 min read
·
Dan Samorodnitsky
